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Aim: Monoacyglycerol acyltransferases (MGATs) are known to play important roles in intestinal TG
absorption. In contrast, the role of MGATs in the liver is still unclear. We investigated the effects of JTP-
103237, a novel MGAT inhibitor, on hepatic MGAT activity and hepatic lipid metabolism.
Results: JTP-103237 reduced hepatic triglyceride content and hepatic MGAT activity in a high sucrose
very low fat (HSVLF) diet induced fatty liver model. Interestingly, JTP-103237 suppressed not only tri-
glyceride (TG) and diacylglycerol (DG) synthesis, but also fatty acid (FA) synthesis (de novo lipogenesis)
in this model. JTP-103237 also suppressed lipogenesis-related gene expression, such as sterol regulatory
element-binding protein 1-c. Moreover, JTP-103237 decreased plasma glucose levels and total choles-
terol and reduced the accumulation of epididymal fats in HSVLF diet fed mice.
Conclusion: In the present study, JTP-103237 prevented carbohydrate-induced fatty liver and suppressed
both TG synthesis and de novo lipogenesis, suggesting MGAT inhibitor may prevent carbohydrate-
induced metabolic disorders, including NAFLD, obesity and diabetes.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common
cause of liver dysfunction worldwide (1, 2). NAFLD is a condition
deﬁned by excessive fat accumulation in the form of triglycerides
(TG) in the liver, namely fatty liver. The exact cause of NAFLD is still
unknown. However, both obesity and insulin resistance likely have
a strong inﬂuence on the disease process. Understandably, with the
growing epidemic of obesity and diabetes, the prevalence and
impact of NAFLD continues to increase (3).
In addition, NAFLD is considered to be associated not only
with obese and diabetes onset, but also with cardiovascular).
rmacological Society.
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d/4.0/).disease (4). Inevitably, the economic burden associated with
NAFLD will increase; however, effective treatments are not yet
available, and hence the need for pharmacological treatments is
fully justiﬁed.
Fatty liver is considered to result from an imbalance of lipid
metabolism (5). Thus, ameliorating hepatic lipid metabolism ap-
pears to be a potential strategy for the treatment of NAFLD and
other related diseases.
There are two major pathways, the glycerol-3-phosphate (G-
3-P) pathway and the monoacylglycerol (MG) pathway, for TG
synthesis (6). The G-3-P pathway is a de novo pathway present in
most tissues. The MGAT pathway plays a predominant role on
dietary fat absorption.
Monoacyglycerol acyltransferases (MGATs) catalyze the ﬁrst
step of TG synthesis. The formation of diacylglycerol (DG) from
MG and fatty acyl CoA facilitated by MGAT is considered thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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(7, 8).
The relevance of MGAT activity to hepatic TG metabolism is still
unclear. However, liver MGAT activity reportedly increases in dia-
betic rats (9) and this pathway is active in neonatal rats (10). In
addition, there is evidence that MGAT2 and MGAT3 were overex-
pressed in patients with NAFLD (11).
In our previous report, we reported our discovery of a novel
MGAT2 inhibitor, JTP-103237, which is a 7-(4,6-Di-tert-butyl-pyr-
imidin-2-yl)-3-(4-triﬂuoromethoxy-phenyl)-5,6,7,8-tetrahydro-
[1,2,4]triazolo[4,3-a]pyrazine derivative (12). JTP-103237 selec-
tively inhibited MGAT2 but not DGAT2 and prevented high fat
diet induced obesity through the inhibition of intestinal MGAT2.
In addition, JTP-103237 reduced hepatic triglyceride content in
high fat diet induced obese mice. However, since JTP-103237
reduced food intake and body weight through the inhibition
of intestinal MGAT, the contribution of liver MGAT activity on
hepatic triglyceride reduction requires further investigation.
In this study, we investigated whether liver MGAT activity is
relevant to hepatic lipid metabolism using JTP-103237.
2. Materials and methods
2.1. Chemicals and reagents
JTP-103237 was synthesized in the Central Pharmaceutical
Research Institute within Japan Tobacco Inc. (Osaka, Japan). [1-14C]
oleoyl-coenzyme A was purchased from Amersham biosciences.
[1-14C] oleic acid, [1-14C] palmitic acid and [1-14C] acetate were
purchased from PerkinElmer Japan. D-[U-14C]-glucose was pur-
chased from GE Healthcare. All other chemicals were standard
reagent grade.
2.2. Animals and diets
Male C57BL/6J mice were purchased from Charles River Labo-
ratories (Yokohama, Japan). Mice were maintained with free access
to water and either a normal chow diet (CRF-1, Charles River Japan)
or a high sucrose very low fat (HSVLF) diet (D08030601, Research
Diets Inc.) The caloric contributions (% fat: % carbohydrate: % pro-
tein; kcal/g) in HSVLF diets as indicated by the manufacturer are
2.6: 76.7: 20.7; 3.53 kcal/g, respectively. Animals were housed
under speciﬁc pathogen-free conditions in a room controlled for
temperature at 23 ± 3 C and humidity of 55 ± 15% in 12-h light/
dark cycles (lights on from 8:00 AM to 8:00 PM). All procedures
were conducted according to guidelines from Japan Tobacco's
Animal Care Committee.
2.3. Measurement of blood chemistry and hepatic triglyceride
content
Blood samples were collected from the orbital vein in fed
state and plasma glucose, triglyceride and total cholesterol levels
were measured by an enzymatic method (glucose: LiquiTech
glucose HK test Roche Diagnostics, Switzerland), triglyceride:
Determiner L TGII (Kyowa Medex Co, Tokyo, Japan), total
cholesterol: Determiner L TCII (Kyowa Medex Co, Tokyo, Japan).
Plasma insulin levels were measured by an ELISA (Rat insulin
assay kit (Morinaga Institute of Biological Science, Tokyo, Japan).
Liver was collected from mice in fed state and a portion of
the liver that was approximately 100 mg, 0.5 ml of methanol,
and zirconia beads were added to tubes. The portion of liver
was homogenized using a mixer mill (MM300 Retch) (25 Hz,
10 min). To the homogenized solution, 1 ml of chloroform was
added and mixed thoroughly. The mixture was then centrifuged(10,000 g, 5 min, 4C) and the resulting supernatant collected.
Solvents contained in 0.5 ml of the supernatant were dried
under a stream of nitrogen gas. To the residue, 0.5 ml of 2-
propanol was added to reconstitute the residue. The TG con-
centration of the 2-propanol solution was determined by an
enzymatic method.
2.4. Evaluation on liver MGAT activity
Liver S9 fractions were isolated through centrifugation as pre-
viously described (12). The MGAT assay was performed at room
temperature in the presence of 100 mM TriseHCl (pH 7.5), 250 mM
Sucrose, 5 mM MgCl2, 0.05% BSA (SigmaeAldrich, St. Louis, MO),
0.05 mM 2-oleoyl glycerol and 25 mM [1-14C] oleoyl-CoA. The
radioactivity of synthesized [1-14C] diacylglycerol was separated
using thin layer chromatography (TLC) and analyzed as MGAT
activity.
2.5. Evaluation of hepatic lipid synthesis
Livers were collected in fed state frommice and a portion of the
liver thatwas approximately 100mgwas added to reactionmedium
(DMEM low glucose containing 500 mM [1-14C] acetate (29.0 mCi/
ml)). After 90 min, the reaction was stopped by fast cooling. Lipids
were extracted from portions of the liver, and separated via TLC
using a hexane:diethylether:acetic acid (80:30:2) solvent system.
The signal intensity of the TG and DG fraction on a TLC plate was
measured using an FLA-7000 imaging system. The radioactivity
equivalent in each sample was calculated using a correction factor
obtained from the standard sample and the ratio of lipid synthesis
per 90 min per gram of liver was also calculated.
The lipid extract was saponiﬁed with 1.5 N NaOH (90 min, 4C).
After saponiﬁcation, lipids were re-extracted and separated via TLC
using the same process described above. The signal intensity of the
fatty acid fraction on a TLC plate was measured and the radioac-
tivity equivalent in each sample was calculated in the samemanner
as previously mentioned. The rate of fatty acid synthesis (de novo
lipogenesis) was calculated as nmol of radioactivity incorporated
into fatty acid fractions per 90 min per gram of liver.
2.6. Evaluation of hepatic lipid components after administration of
fatty acids
10-week old male C57BL/6J mice were acclimatized to an HSVLF
diet for 5 weeks. JTP-103237 was administered orally to mice in fed
state at a dose of 100 mg/kg. After 60 min, 30 mM/kg of oleic acid
containing 135 mCi/kg of [1-14C] oleic acid was intraperitoneally
administered. After 15 min, mice were sacriﬁced and a portion of
the liver that was approximately 350 mg was collected. Lipids were
extracted and separated via TLC. The signal intensity of TG, DG fatty
acid and phospholipid fractions on a TLC plate were measured
using an FLA-7000 imaging system as described above. The ratio of
each lipid component to total lipids was calculated.
2.7. mRNA quantiﬁcation with real-time quantitative PCR
Total RNA was extracted from the liver. RNA was transcribed
into cDNA using M-MLV reverse transcriptase and random primers
(Invitrogen, Carlsbad, CA). The reaction mixture was incubated for
10 min at 25 C, 1 h at 37 C, and 5 min at 95 C. Real-time PCR
quantiﬁcation was performed in a 50-mL reaction mixture with
an automated sequence detector combined with the ABI Prism
7700 Sequence Detection System software (Applied Biosystems,
Foster City, CA). The reaction mixture contained 50 ng of syn-
thesized cDNA, 3.5 mM MgCl2, 0.3 mM primers, 0.1 mM probes, and
C. Okuma et al. / Journal of Pharmacological Sciences 128 (2015) 150e1571521.25 units of Ampli Taq Gold®. Cycle parameters were 10 min at
95 C, followed by 40 cycles of 15 s at 95 C and 60 s at 60 C. The
expression of mRNA levels were normalized using 18s rRNA levels.
The following primers and FAM-conjugated probes were designed
using Primer Express software (Applied Biosystems): sterol
regulatory element-binding protein 1-c (SREBP-1c) (forward,
ATCGGCGCGGAAGCTGTCGGGGTAGCGTC; reverse, TGAGCTGGAGC
ATGTCTTCAA; probe, ACCACGGAGCCATGGATTGCACATT), stearoyl-
CoA desaturase 1 (SCD-1) (forward, TCTCCAGTTCTTACACGACC
ACC; reverse, GGACGGATGTCTTCTTCCAGGT; probe, CCTCCGGAAAT
GAACGAGAGAAGGTGAAG), fatty acid synthase (FAS) (forward,
GGTCTATGCCACGATTCTGAAT; reverse, GGAATGTTACACCTTGCTC
CTT; probe, CACCAATACAGATGGCAG), Acetyl-CoA carboxylase
(ACC) (forward, TGGATGATGGTCTGAAGGCAG; reverse, CCTCTGAG
GCCTTGATCATCAC; probe, TGAGGAAGTTGGCTATCC), mitochon-
drial glycerol 3-phosphate acyltransferase (mtGPAT) (forward,
GCAATGGCGTACTTCATGTGTT; reverse, CATGGAAGCCATCATAGCTT
GCAGCATC; probe, GCACCTCTTATTCAGGACTGCA), diacyl glycer-
olacyltransferase 2 (DGAT2) (forward, ATCCTCATGTACACCTTCTG
CACAG; reverse, ACCTGGCTGGCATTTGACTGGAACA; probe, ATCTC
CTGCCACCTTTCTTGG), and 18s rRNA (purchased from Applied
Biosystems).2.8. Glucose utilization in fat tissue
Small portions (approximately 200 mg) of epididymal and
mesenteric adipose tissues were incubated in Hank's balanced salt
solution (pH7.4) containing D-[U-14C]-glucose in the absence or
presence of insulin (1 or 10 nmol/l) at 37 C for 2 h. After stopping
the reaction through the addition of 0.05 mol/l H2SO4, the 14CO2
produced was trapped in ﬁlter paper. Radioactivity in the ﬁlterC
5 wks of age
Scarified 
(at 37 days after 
treatment)
Fed HSVLF diets
Treatment with 
JTP-103237 for 37 days
Blood 
collection
(at 24 days after 
treatment)
14 days
A  
##
*
7 wks of age 10 wks of age 12 wks of age
Fig. 1. Hepatic triglycerides and MGAT activity after chronic treatment with JTP-103237.
administered as a food admixture (the ﬁnal dosages were 33 mg/kg/day in the 30 mg/kg grou
state and livers were collected. Hepatic triglyceride content and MGAT activity were measur
Hepatic triglycerides (B), MGAT activity (C) and the relationship between both (D) are shown
normal chow group). *P < 0.05, **P < 0.01 vs. control (Dunnett's), ##P < 0.05 vs. normal cpaper was measured using a liquid scintillation counter (TRI-CARB
2500TR, Packard BioScience, Waltham, MA, USA).
2.9. Statistical analysis
Data are expressed as the mean ± standard deviation (SD). All
statistical analysis was performed with statistical software
Statlight 2000 (Yukms Corp., Tokyo, Japan). A Student's t-test
was performed provided that homogeneity was conﬁrmed by an
F test. In the case that homogeneity was not conﬁrmed by an
F test, a Welch's test was performed. A Dunnett's multiple
comparison test was performed in the multiple-group study
provided that homogeneity was conﬁrmed by a Bartlett's ho-
moscedasticity test. In the case that homogeneity was not
conﬁrmed by a Bartlett's homoscedasticity test, a Steel's multiple
comparison test was performed. A Pearson correlation test was
used to analyze the correlation between hepatic triglyceride
levels and MGAT activity. Differences were considered signiﬁcant
if P was <0.05 (2-sided).
3. Results
3.1. Effects on hepatic triglycerides and liver MGAT activity in HSVLF
diet fed mice
To investigate whether JTP-103237 decreases liver lipid syn-
thesis by inhibiting liver MGATactivity, hepatic triglyceride content
in HSVLF diet fed mice was evaluated.
In HSVF fed mice, hepatic triglyceride levels and MGAT activity
increased as compared to those in normal diet fedmice. The level of
liver MGAT activity in this study was 6.3*105 nmol/mg/minB  
D
##
5-week old mice were fed HSVLF diet for two weeks. Subsequently, JTP-103237 was
p and 111 mg/kg/day in the 100 mg/kg group). After 37 days, mice were sacriﬁced in fed
ed as described in the materials and methods section. The scheme of the treatment (A),
. Data represent the mean ± S.D (n ¼ 8/group in the HSVLF diet fed groups, n ¼ 6 in the
how fed group (Student's t-test). In the ﬁgure (C), **P < 0.01 by Pearson tests.
Table 1
Biochemical parameters in JTP-103237 treated mice fed an HSVLF diet. 5-week old mice were fed HSVLF diet for two weeks. Subsequently, JTP-103237 was administered as a
food admixture (the ﬁnal dosages were 33 mg/kg/day in the 30 mg/kg/day group and 111 mg/kg/day in the 100 mg/kg/day group). On Day 24, blood was collected from the
orbital vein in fed state and plasma glucose, insulin, triglyceride and total cholesterol levels were measured. The values for body weight and cumulative food intake were those
obtained on Day 37. On day 37, epididymal fat was collected and wet weight was measured. Data represent the mean ± S.D (n ¼ 8/group in the HSVLF diet fed groups, n ¼ 6 in
the normal chow group).
Chow Normal HSVLF
Treatment None None JTP-103237
30 mg/kg/day
JTP-103237
100 mg/kg/day
Body weight (g) 27.5 ± 0.2 27.2 ± 1.8 26.9 ± 0.7 26.7 ± 1.7
Cumulative food intake (g) 122 ± 4 113 ± 7d 116 ± 4 116 ± 8
Epididymal fat weight (g) 0.54 ± 0.06 0.65 ± 0.15 0.60 ± 0.10 0.49 ± 0.11a
Glucose (mg/dl) 186 ± 14 215 ± 41 197 ± 26 179 ± 18a
Insulin (mg/dl) 2.0 ± 2.0 3.5 ± 2.1 1.5 ± 1.1c 1.7 ± 0.8
Triglycerides (mg/dl) 144 ± 23 74 ± 26d 59 ± 13 58 ± 21
Total cholesterol (mg/dl) 103 ± 2 125 ± 16e 123 ± 10 96±9b
a P < 0.05.
b P < 0.01 vs. control (Dunnett's test).
c P < 0.05 vs. control (a Steel's multiple comparison test).
d P < 0.05 vs. normal chow fed group (Student's t-test).
e P < 0.01 vs. normal chow fed group (Student's t-test).
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statistically signiﬁcant, JTP-103237 tended to decrease hepatic tri-
glyceride in particular 100 mg/kg/day. In 30 mg/kg/day treated
group, these changes were not clear. JTP-103237 decreased MGAT
activity at a dose of 100 mg/kg/day (Fig. 1BeC). In addition,
there was a statistically signiﬁcant correlation between hepatic TG
and MGAT activity (Fig. 1D). Hepatic triglycerides were evaluated
again in additional study at 100 mg/kg/day of JTP-103237 for 21
days. The results showed that JTP-103237 signiﬁcantly decreased
hepatic triglyceride (45.0 ± 5.5 mg/g liver in vehicle group and
27.1 ± 7.3 mg/g liver, respectively. P < 0.01 in Student's t-test).3.2. Effects on body weight, food intake, fat weight and biochemical
parameters in HSVLF diet fed mice
As shown in Table 1, JTP-103237 did not alter body weight
and cumulative food intake in HSVLF diet fed mice. On the other
hand, JTP-103237 decreased fat weight, plasma glucose and
total cholesterol levels at a dose of 100 mg/kg/day. In addition,
plasma insulin levels were tended to be decreased in JTP-103237
treated groups and it was statistically signiﬁcant at 30 mg/kg/day.A  
Fig. 2. TG, DG and fatty acid synthesis from acetate in isolated liver tissues after chronic tr
sequently, JTP-103237 was administered as a food admixture (the ﬁnal dosage was 104 mg/kg
were collected. The rate of TG and DG synthesis from acetate was evaluated as described in
saponiﬁcation was evaluated as fatty acid synthesis (de novo lipogenesis). Data represent the
vs. control (Welch's t test).Although, these values were not statistically signiﬁcant, JTP-103237
tended to decrease plasma triglyceride levels.
3.3. Effect on hepatic lipid synthesis in HSVLF diet fed mice
Subsequently, the effect of chronic treatment of JTP-103237 on
hepatic lipid synthesis in isolated liver tissues in HSVLF diet fed
mice was evaluated. JTP-103237 signiﬁcantly suppressed TG and
DG synthesis from acetates (Fig. 2A). In addition, lipid extracts were
saponiﬁed through treatment with NaOH to investigate de novo
lipogenesis (fatty acid synthesis). As a result, JTP-103237 also
signiﬁcantly decreased de novo lipogenesis (Fig. 2B).
In order to clarify the time sequence of the effects, lipogenesis
after a single or subchronic treatment of JTP-103237 was evaluated.
JTP-103237 signiﬁcantly suppressed lipogenesis after 7 days of
treatment but did not suppress lipogenesis after a single treatment
(Fig. 3).
3.4. Effect on lipogenic gene expression
The mRNA levels of lipogenic genes (SREBP-1c, SCD-1, FAS, ACC,
mtGPAT and DGAT2) in the liver in chronic JTP-103237 treatedB
eatment with JTP-103237. (A) 7-week old mice were fed HSVLF diet for 1 week. Sub-
/day in the 100 mg/kg group). After 21 days, mice were sacriﬁced in fed state and livers
the materials and methods section. (B) Using the sample in (A), fatty acid content after
mean ± S.D. (n ¼ 5/group). *P < 0.05, **P < 0.01 vs. control (Student's t-test), yyP < 0.01
Fig. 3. Lipogenesis after a single or 7 days of treatment with JTP-103237. 7-week old
mice were fed HSVLF diet for 1 week. In the single dosing experiment, JTP-103237 was
administered orally at a dose of 100 mg/kg. After 60 min, mice were sacriﬁced in fed
state and livers were collected. In the study with 7 days dosing, JTP-103237 was
administered as a food admixture (the ﬁnal dosage was 104 mg/kg/day in the 100 mg/
kg group). After 7 days, mice were sacriﬁced in fed state and livers were collected. The
rate of fatty acid synthesis (de novo lipogenesis) from acetate was evaluated as
described in the materials and methods section for both experiments. Data represent
the mean ± S.D. (n ¼ 5/group). *P < 0.05 vs. control (Student's t-test).
Table 2
Lipid composition after administration of 14C oleic acid in JTP-103237 treated mice
fed an HSVLF diet. 10-week old male C57BL/6J mice were acclimatized to an HSVLF
diet for 5 weeks. JTP-103237 was administered orally to mice in fed state at a dose of
100mg/kg. After 60min, 30 mM/kg of oleic acid containing 135 mCi/kg of [1-14C] oleic
acid was intraperitoneally administered. After 15 min, mice were sacriﬁced and
hepatic lipids were extracted. The signal intensity of TG, DG, fatty acid and phos-
pholipid fractions on a TLC plate and the ratio of each lipid component to total lipids
were calculated. Data represent the mean ± S.D (n ¼ 6/group).
TG (%) DG (%) Fatty acid (%) Phospholipid (%)
Control 72.1 ± 2.2 17.7 ± 2.9 5.0 ± 0.5 5.0 ± 0.9
JTP-103237 69.8 ± 1.3 20.0 ± 1.6 5.5 ± 0.3a 4.9 ± 0.9
a P < 0.05 vs. control (Student's t-test).
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SCD-1 and DGAT2 genes expression was signiﬁcantly decreased in
JTP-103237 treated mice as compared to control (Fig. 4). FAS, ACC
and mtGPAT genes expression did not yield statistically signiﬁcant
differences due to the large variability observed, but tended to
decrease as compared to control.3.5. Effects on hepatic lipid components after administration of
fatty acids
The amount of lipid components after a single treatment of JTP-
103237 was subsequently analyzed using 14C labeled oleic acid. The
differences were not statistically signiﬁcant; however, JTP-103237
tended to decrease the ratio of TG (product of MGAT) to total
labeled lipids (P ¼ 0.06). In addition, JTP-103237 signiﬁcantly
increased the ratio of fatty acids (substrate of MGAT) to total labeled
lipids (Table 2). However, since separating the bands for MG was
difﬁcult, the amount of MG could not be evaluated in this experi-
ment. The ratio of DG did not change in this study, which was likelyFig. 4. Effects of JTP-103237 on lipogenic gene expressions. 6-week old mice were fed HSVL
ﬁnal dosage was 102 mg/kg/day in the 100 mg/kg group). After 29 days, mice were sacriﬁc
lipogenic gene expression was measured using quantitative real-time PCR. Data representdue to the difﬁculty in determining DG levels, since DG is an in-
termediate product of triacylglycerol synthesis.
3.6. Effects on insulin sensitivity in isolated fat tissues
To investigate the effects of JTP-103237 in other tissues, adipose
glucose oxidation in HSVLF diet fed mice was evaluated. Glucose
oxidation capability increased with insulin in both epididymal and
mesenteric fat tissue. As shown in Fig. 5, it was not statistically
signiﬁcant, but glucose oxidation in JTP-103237 treated adipose
tissues tended to increase and these effects with insulin were
clearer than those without insulin. The P value in mesenteric fat
tissue with 10 nM insulin was 0.0977.
4. Discussion
MGATs are known to play important roles in intestinal TG
absorption. In addition to intestinal MGAT activity, there are a
few reports describing liver MGAT activity (9e11). Regarding
subtype, very low expression levels of both MGAT1 and MGAT2
were reportedly detected in mouse liver (13, 14) Although it was
shown that systemic Mogat2 deﬁcient mice are resistant to high
fat diet induced obesity and fatty livers (15), the role of hepatic
MGAT has been still unclear. On the other hand, in a recent
report, it was indicated MGAT2 in extraintestinal tissues may
contribute to the regulation of energy metabolism (16, 17). For
example, intestine-speciﬁc expression of Mogat2 in systemic
Mogat2 deﬁcient mice partly restored the metabolic changes. In
addition, MGAT1 antisense oligonucleotides treatment, report-
edly, improved fatty liver and hepatic insulin sensitivity (18).F diet for 1 week. Subsequently, JTP-103237 was administered as a food admixture (the
ed in fed state and livers were collected. Total RNA was extracted from the livers and
the mean ± S.D. (n ¼ 6/group). **P < 0.01 vs. control (Student's t-test).
A   B  
Fig. 5. Glucose utilization in epididymal fat tissue (A) and mesenteric fat tissue (B) after chronic treatment with JTP-103237. 7-week old mice were fed HSVLF diet for 1 week.
Subsequently, JTP-103237 was administered as a food admixture (the ﬁnal dosage was 104 mg/kg/day in the 100 mg/kg group). After 44days, mice were sacriﬁced in fed state and a
small portion of epididymal and mesenteric adipose tissues were collected. Glucose utilization was measured in the absence or presence of insulin (1 or 10 nmol/l). Data represent
the mean ± S.D. (n ¼ 5/group).
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particular hepatic MGAT, might be involved in hepatic lipid
metabolism.
In the present study, we investigated the effects of MGAT inhi-
bition on hepatic lipid metabolism using JTP-103237, a novel MGAT
inhibitor. As shown in previous report, JTP-103237 inhibited
MGAT2 activity, but did not inhibit DGAT2 activity, which belongs
to the same family as MGAT (12). In addition, the IC50 value for
MGAT3 was approximately 300 times higher than that of MGAT2.
However, we have not evaluated the effect of JTP-103237 onMGAT1
activity since we could not obtain the membrane fraction which
exhibited sufﬁcient MGAT1 activity. Therefore, there is a probability
that JTP-103237 inhibits not only MGAT2 but MGAT1 in the present
study.
In order to focus on liver MGAT activity, we used HSVLF diets in
the present study, which induced fatty livers due to high sucrose
content (19). Since the caloric contribution of fat in HSVLF diet was
only 2.6%, the effects by intestinal MGAT inhibition were consid-
ered small. Indeed, JTP-103237 did not reduce body weight and
food intake in HSVLF diet fed mice in the present study in contrast
to previous report using high fat diet fed mice (12).
Although the values were not statistically signiﬁcant, JTP-
103237 tended to decrease hepatic triglyceride in this study. In
addition, in the reproducibility study, JTP-103237 signiﬁcantly
decreased hepatic triglycerides at 100 mg/kg/day. Taken together, it
is considered JTP-103237 decreased hepatic triglycerides in HSVLF
diet fed mice. Moreover, the relationship between hepatic TG
content and MGAT activity was signiﬁcantly correlated, suggesting
that decreases in carbohydrate-induced fatty liver might be due to
hepatic MGAT inhibition.
We next investigated lipid synthesis in the liver in HSVLF diet
fed mice after chronic treatment with JTP-103237. JTP-103237
decreased TG and DG synthesis after chronic treatment. These
results were within expectation; however, surprisingly, JTP-
103237 decreased fatty acid synthesis from acetate (de novo
lipogenesis).
MGAT catalyzes the synthesis of DG from MG and is the key
enzyme for triglyceride synthesis. Understandably, this is not
relevant to fatty acid synthesis. We suspected non-speciﬁc inhibi-
tory effects on enzymes related to fatty acid synthesis and we, thus,
investigated the effects of JTP-103237 on lipogenesis after a single
treatment. Results demonstrated that JTP-103237 did not decrease
de novo lipogenesis after a single treatment but decreased lipo-
genesis after 7 days of treatment. From these ﬁndings, the decreasein de novo lipogenesis by JTP-103237 is considered to be not due to
an acute effect of hepatic MGAT inhibition.
Next, to understand how JTP-103237 decreased carbohydrate-
induced fatty liver, we analyzed genes involved in lipogenesis.
Interestingly, the expression of SREBP-1c, SCD1 and DGAT2 genes
was signiﬁcantly decreased with chronic treatment of JTP-103237.
Preliminarily, the expression of MGAT1 and MGAT2 gene were
also evaluated. The expression of MGAT1 was not changed and that
of MGAT2 tended to be decreased (P ¼ 0.078, Student's t-test).
However, since the copy number of these mRNA was low in com-
parison with other mRNAs, the data have not been shown. In
addition, the expression of LXR and other SREBPs were not evalu-
ated but these are subjects for future investigation.
SREBP-1c is a key regulator of fatty livers (20) and the over-
expression of SREBP-1c in the liver of transgenic mice is known to
manifest as severe fatty livers (21). SREBP-1c is predominantly
involved in the regulation of insulin-responsive genes, which
control lipogenesis (22). In particular, SCD1, which is regulated via
SREBP-1c, plays an important role in fatty liver and insulin resis-
tance (23). Indeed, liver-speciﬁc SCD1 deﬁciency completely
blocked carbohydrate-induced lipogenesis (24).
Fatty acids, which are substrates of MGAT, are known to inhibit
SREBP-1c expression by antagonizing activation of the liver X
receptor (LXR) signaling (25, 26). We hypothesized that fatty
acids accumulated by inhibiting hepatic MGAT might inhibit LXR
activation and consequent SREBP-1c expression. Next, to investi-
gate this hypothesis, we evaluated the effects of a single treatment
of JTP-103237 on hepatic lipid components after administration of
fatty acids. Results demonstrated that JTP-103237 signiﬁcantly
increased the ratio of fatty acids, and tended to decrease the ratio of
TG in liver. These results suggested the possibility that hepatic
MGAT inhibition may decrease not only TG synthesis, but also de
novo lipogenesis via suppression of LXR/SREBP-1c signaling
pathway by increasing fatty acid. As described above, JTP-103237
decreased DGAT2 gene expression. It is known that DGAT2, which
is strongly involved in fatty liver (27), was not regulated by SREBP-
1c but LXR (28, 29). This result also indicated that JTP-103237
modulates the LXR/SREBP-1c signaling pathway. Our postulated
mechanisms on the decrease in hepatic lipid synthesis by JTP-
103237 are shown in Fig. 6.
The World Gastroenterology Organization stated that NAFLD
and nonalcoholic steatohepatitis (NASH) represent a major global
public health problem that is pandemic (2). However, there are
no speciﬁc drugs for the treatment of these diseases. Recently,
SREBP1c 
Fatty acid 
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Lipogenic Enzymes 
 
: Direct inhibition by JTP-103237 
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Fig. 6. Postulated mechanisms on decrease in hepatic lipid synthesis by an MGAT
inhibitor. TG synthesis via the MGAT pathway may be suppressed through the direct
inhibition of MGAT. As a result of MGAT inhibition, fatty acids, which are substrates of
MGAT, may increase and it suppresses SREBP-1c and related gene expression via
antagonizing LXR signaling (secondary effects through the inhibition of MGAT). He-
patic TG lipid synthesis would be suppressed by the MGAT inhibitor via direct and
indirect (secondary) effects.
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ered to be a potential therapeutic strategy for NAFLD (30). The
contribution of de novo lipogenesis to total hepatic triglyceride
production in normal subjects is small. However, the contribution
of de novo lipogenesis to total hepatic triglyceride production in
patients with NAFLD is much higher (31). In the present study,
JTP-103237 prevented carbohydrate-induced fatty liver and sup-
pressed both TG synthesis and de novo lipogenesis, suggesting
that MGAT inhibition might be potential target for treatment of
NAFLD and NASH.
JTP-103237 decreased plasma glucose levels and total choles-
terol, reduced the accumulation of epididymal fats and tended to
decrease plasma insulin levels. Since it had been observed the
reduction of fat tissue and plasma insulin levels, the insulin
sensitivity in adipose tissuewas investigated. Although the changes
were not statistically signiﬁcant due to large variation, JTP-103237
tended to increase adipose tissue glucose oxidation with insulin in
HSVLF diet fed mice. In mesenteric fat tissue, the percentages for
control group with insulin were 193% and 148% (with 1 and 10 nM
insulin, respectively) whereas that without insulinwas 125%. There
is room for further investigation regarding the role of MGAT in
extraintestinal tissue including muscle, but it may be probable that
MGAT involves in systemic energy metabolism and insulin
sensitivity.
From these ﬁndings, JTP-103237 is expected to display beneﬁcial
effects in the treatment of carbohydrate induced metabolic disor-
ders, including NAFLD, adiposity and diabetes. In our previous
report, JTP-103237 also prevented fat induced obesity, fatty liver
formation and glucose intolerance (12). Taken together, MGAT in-
hibitor would be effective in metabolic diseases, regardless of
whether these diseases are caused by excessive fat intake or car-
bohydrate intake.
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